ProstatID™ is North America's first and only FDA-Cleared AI software for the Screening, Detection (CADe) and Diagnosis (CADx) of Prostate Cancer. It received FDA clearance on June 23, 2022 and is now used as the benchmark against which the FDA evaluates other prostate AI solutions.

Why trust it?

• Proven accuracy: With 93.6% sensitivity-specificity (AUROC), physicians can reliably detect and diagnose prostate cancer with far less interpretation time, higher confidence, and significantly improved positive detection rates while decreasing false positives.
• Rigorous clinical validation: Bot Image conducted two clinical studies involving 25 physicians and 300 prostate MRI cases over two years. The results exceeded the FDA threshold, demonstrating statistically significant improvement in reader performance.
• Trained on real outcomes: The program was trained using thousands of digital images, radiologist interpretations, and biopsy results.
• Works across MRI systems: Whether it is a Philips, GE, or Siemens (1.5T or 3.0T) MRI, ProstatID can process prostate MRIs. It doesn't require the same image quality as an interpreting physician.
• Trusted by specialists: "ProstatID allows three-dimensional view of the relevant findings synthesized from the hundreds of images obtained during multiparametric prostate MRI," noted Dr. Eric Walser, Chairman of Radiology at UT Medical Branch.

ProstatID has proven in clinical studies to not only reduce the number of false positives but also increase the number of early cancer detections.

ProstatID has also been CE-Marked (EU) and UKCA-Certified (UK).

‍
^{More information about ProstatID}